JP2023524047A - 細胞の培養方法 - Google Patents
細胞の培養方法 Download PDFInfo
- Publication number
- JP2023524047A JP2023524047A JP2022566107A JP2022566107A JP2023524047A JP 2023524047 A JP2023524047 A JP 2023524047A JP 2022566107 A JP2022566107 A JP 2022566107A JP 2022566107 A JP2022566107 A JP 2022566107A JP 2023524047 A JP2023524047 A JP 2023524047A
- Authority
- JP
- Japan
- Prior art keywords
- aspects
- concentration
- medium
- potassium ions
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4234—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016907P | 2020-04-28 | 2020-04-28 | |
| US63/016,907 | 2020-04-28 | ||
| PCT/US2021/029762 WO2021222479A1 (en) | 2020-04-28 | 2021-04-28 | Methods for culturing cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524047A true JP2023524047A (ja) | 2023-06-08 |
| JP2023524047A5 JP2023524047A5 (cg-RX-API-DMAC10.html) | 2024-05-13 |
Family
ID=75954306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566107A Pending JP2023524047A (ja) | 2020-04-28 | 2021-04-28 | 細胞の培養方法 |
Country Status (11)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4121447A1 (en) | 2020-03-20 | 2023-01-25 | Lyell Immunopharma, Inc. | Novel recombinant cell surface markers |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4284395A4 (en) * | 2021-02-01 | 2025-01-08 | University Health Network | ENHANCED T CELLS FOR CANCER THERAPY USING AMINO ACID STARVATION PATHWAYS |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2023076577A2 (en) * | 2021-10-28 | 2023-05-04 | Memorial Sloan-Kettering Cancer Center | Methods for modulating cell pluripotency and self-renewal property |
| WO2023076511A1 (en) * | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods of generating cells |
| WO2023163560A1 (ko) | 2022-02-25 | 2023-08-31 | 주식회사 강스템바이오텍 | 마이크로캐리어를 이용한 줄기세포 배양 방법 |
| CN118891359A (zh) | 2022-02-25 | 2024-11-01 | 康干细胞生物科技有限公司 | 使用无血清培养基的干细胞培养方法 |
| CN114958737B (zh) * | 2022-03-28 | 2024-02-09 | 苏州系统医学研究所 | 一种干性记忆t细胞的体外扩增方法及其应用 |
| IT202200010535A1 (it) | 2022-05-20 | 2023-11-20 | Humanitas Mirasole Spa | Cellule t cd8+ potenziate per l'immunoterapia del cancro |
| WO2024218715A1 (en) | 2023-04-19 | 2024-10-24 | Btl Healthcare Technologies A.S. | Culture media based on protein hydrolysate and a process for preparing thereof |
| US12668774B2 (en) | 2023-10-12 | 2026-06-30 | Btl Healthcare Technologies A.S. | Product, system and method of cell cultivation |
| WO2025235403A1 (en) * | 2024-05-06 | 2025-11-13 | Vertex Pharmaceuticals Incorporated | Differentiation of pancreatic islet cells |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107074975A (zh) * | 2014-08-28 | 2017-08-18 | 生物蛋白有限公司 | 用于修饰的t细胞的条件活性嵌合抗原受体 |
| WO2019072889A1 (en) * | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | MEDIUM OF INFUSION |
| JP2020511978A (ja) * | 2017-03-31 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 灌流培地 |
Family Cites Families (201)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| AU645488B2 (en) | 1989-02-21 | 1994-01-20 | Terumo Corporation | A process for the generation of proliferating CD4 lymphocytes |
| EP0475972A4 (en) | 1989-05-15 | 1992-05-20 | E.I. Du Pont De Nemours And Company | Improved culture of human tumor-infiltrating lymphocytes by combining gas permeable bags and a primary culture container |
| IT1261180B (it) | 1993-02-10 | 1996-05-09 | Metodo di propagazione in vitro di cellule til. | |
| US5968755A (en) | 1995-09-27 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining T-cell profiles of immunocompromised subjects |
| EP0914416B1 (en) | 1996-03-30 | 2002-06-12 | Science Park Raf S.p.A. | Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors |
| US20020081635A1 (en) | 2000-05-11 | 2002-06-27 | Thomas Terry E. | Novel antibody compositions for preparing enriched T cell preparations |
| US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| EP3254687A1 (en) | 2001-10-04 | 2017-12-13 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 receptor activity |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| AU2002353822B2 (en) | 2002-10-15 | 2008-11-06 | The Government Of The United States Of America Represented By The Secretary Department Of Health And Human Services | Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer |
| US7381405B2 (en) | 2002-10-15 | 2008-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer |
| US20050249712A1 (en) | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| EP1814580B1 (en) | 2004-11-24 | 2016-08-10 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| EP1909827A4 (en) | 2005-06-09 | 2010-03-10 | Gal Markel | MODULATION OF IMMUNITY AND CEACAM1 ACTIVITY |
| WO2007040105A1 (ja) | 2005-09-30 | 2007-04-12 | Takara Bio Inc. | T細胞集団の製造方法 |
| US20090246212A1 (en) | 2005-09-30 | 2009-10-01 | Kyoto University | Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic |
| WO2007071390A1 (en) | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating malignant melanoma |
| US8007785B2 (en) | 2005-12-21 | 2011-08-30 | Sentoclone International Ab | Method for treating colon cancer with tumour-reactive T-lymphocytes |
| WO2008033403A2 (en) | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Agents and methods to elicit anti-tumor immune response |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
| FR2911346B1 (fr) | 2007-01-12 | 2012-12-07 | Ct Hospitalier Universitaire De Nantes | Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til |
| WO2008133772A1 (en) | 2007-04-26 | 2008-11-06 | Ludwig Institute For Cancer Research | Method for modulating activity of t lymphocytes |
| AU2009314704A1 (en) | 2008-11-13 | 2010-05-20 | Instituto De Medicina Molecular | Foxp3+ natural kiler T-cells and the treatment of immune related diseases |
| WO2010065959A1 (en) | 2008-12-05 | 2010-06-10 | Northeastern University | Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| US9512401B2 (en) | 2010-10-01 | 2016-12-06 | Board Of Regents, The University Of Texas System | B and T lymphocyte attenuator marker for use in adoptive T-cell therapy |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| RU2011130448A (ru) | 2011-07-22 | 2013-01-27 | Зао "Евроген" | Методы и наборы для увеличения разнообразия т-клеток |
| HK1199402A1 (en) | 2011-09-21 | 2015-07-03 | 干细胞医药有限公司 | Beta-lactam compounds for enhancing t cell -mediated immune responses |
| US9315774B2 (en) | 2011-10-21 | 2016-04-19 | Cell Medica Limited | Device for the aseptic expansion of cells |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| EP2822578A4 (en) | 2012-03-07 | 2015-10-07 | Childrens Medical Center | FABRIC CONSTRUCTS AND USES THEREOF |
| WO2013167136A1 (en) | 2012-05-08 | 2013-11-14 | Herlev Hospital | Improving adoptive cell therapy with interferon gamma |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| WO2014201378A1 (en) | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
| WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
| US9886736B2 (en) | 2014-01-20 | 2018-02-06 | Nvidia Corporation | Selectively killing trapped multi-process service clients sharing the same hardware context |
| EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| ES2777304T3 (es) | 2014-02-21 | 2020-08-04 | Colmmune Inc | Células TSCM y métodos de uso |
| EP3698850A1 (en) | 2014-03-20 | 2020-08-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
| US10016421B2 (en) | 2014-04-05 | 2018-07-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination |
| ES2980788T3 (es) | 2014-04-10 | 2024-10-03 | H Lee Moffitt Cancer Ct & Res | Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva |
| RU2708199C2 (ru) | 2014-06-10 | 2019-12-04 | Полибайосепт Аб | Культуральная среда для клеточной иммунотерапии |
| UA123821C2 (uk) | 2014-06-11 | 2021-06-09 | Полібіосепт Гмбх | Композиція для експансії лімфоцитів in vitro |
| EP4270006A3 (en) | 2014-06-13 | 2024-01-10 | Immudex ApS | General detection and isolation of specific cells by binding of labeled molecules |
| SG11201702191YA (en) | 2014-09-17 | 2017-04-27 | Univ Johns Hopkins | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| ES2738705T3 (es) | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| ES2924709T3 (es) | 2014-10-02 | 2022-10-10 | Us Health | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer |
| RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| WO2016085946A1 (en) | 2014-11-24 | 2016-06-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Active cxcr4+ immune cells and methods for their production and use |
| RU2745999C1 (ru) | 2014-12-05 | 2021-04-05 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| MX381241B (es) | 2015-04-27 | 2025-03-12 | Cancer Research Tech Ltd | Composición de células t para usarse en el tratamiento del cáncer. |
| FR3040396A1 (fr) | 2015-06-30 | 2017-03-03 | Chu Nantes | Procede de cryoconservation de lymphocytes infiltrant la tumeur |
| HK1256130A1 (zh) | 2015-07-21 | 2019-09-13 | City Of Hope | 用於嵌合抗原受体和其他受体的表达的t细胞 |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| IL292504B2 (en) | 2015-10-20 | 2024-01-01 | Kite Pharma Inc | -methods of preparing t cells for t cell therapy |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| GB201519340D0 (en) | 2015-11-02 | 2015-12-16 | Cambridge Entpr Ltd | Methods of T-lymphocyte expansion |
| WO2017087784A1 (en) | 2015-11-18 | 2017-05-26 | Duke University | Tumor infiltrating lymphocytes for treatment of cancer |
| KR20180099768A (ko) | 2015-12-30 | 2018-09-05 | 노파르티스 아게 | 증진된 효능을 갖는 면역 이펙터 세포 요법 |
| WO2017117521A1 (en) | 2015-12-31 | 2017-07-06 | Berkeley Lights, Inc. | Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide |
| US11382886B2 (en) | 2016-01-15 | 2022-07-12 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| GB201601868D0 (en) | 2016-02-02 | 2016-03-16 | Lytix Biopharma As | Methods |
| US20180135011A1 (en) | 2017-03-13 | 2018-05-17 | Berkeley Lights, Inc. | Selection and cloning of t lymphocytes in a microfluidic device |
| GB201608060D0 (en) | 2016-05-09 | 2016-06-22 | Univ Birmingham | Method of culturing T cells |
| US12048717B2 (en) | 2016-06-03 | 2024-07-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (TILS) |
| CN117731763A (zh) | 2016-06-24 | 2024-03-22 | 麦克马斯特大学 | 过继细胞转移与溶瘤病毒组合疗法 |
| US11141434B2 (en) | 2016-07-07 | 2021-10-12 | Iovance Biotherapeutics, Inc. | Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof |
| WO2018032088A2 (en) | 2016-08-17 | 2018-02-22 | University Health Network | Regulation of tumor-associated t cells |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| CA3037002A1 (en) | 2016-09-23 | 2018-03-29 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory t cells |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| CN110199015A (zh) | 2016-09-30 | 2019-09-03 | 波赛达治疗公司 | 修饰干细胞记忆t细胞、其制造方法与使用方法 |
| WO2018059549A1 (en) | 2016-09-30 | 2018-04-05 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| WO2018072105A1 (zh) | 2016-10-19 | 2018-04-26 | 中山大学 | 一种干细胞样记忆性t细胞体外诱导剂及方法 |
| CN110099998A (zh) | 2016-10-26 | 2019-08-06 | 艾欧凡斯生物治疗公司 | 冷冻保存的肿瘤浸润淋巴细胞的再刺激 |
| EP3532075A4 (en) | 2016-10-27 | 2020-07-08 | Intima Bioscience, Inc. | VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US20190262400A1 (en) | 2016-10-31 | 2019-08-29 | H. Lee Moffitt Cancer Center And Research Institure, Inc. | Artificial antigen presenting cells for expanding immune cells for immunotherapy |
| TWI826360B (zh) | 2016-11-17 | 2023-12-21 | 美商艾歐凡斯生物治療公司 | 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法 |
| WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| AU2018205234B2 (en) | 2017-01-06 | 2024-09-19 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists |
| ES3055314T3 (en) | 2017-01-06 | 2026-02-11 | Iovance Biotherapeutics Inc | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| US11157880B2 (en) | 2017-01-09 | 2021-10-26 | International Business Machines Corporation | Enforcement of services agreement and management of emotional state |
| CN106834228B (zh) | 2017-01-17 | 2021-03-23 | 上海新长安生物科技有限公司 | 一种体外扩增cd8+t细胞及其细胞亚群的方法 |
| CA3052463A1 (en) * | 2017-02-03 | 2018-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US20200087625A1 (en) | 2017-03-30 | 2020-03-19 | Dennis A. Carson | Methods for isolating, expanding and administering cancer specific cd8+ t cells |
| EP3600357A4 (en) | 2017-03-31 | 2021-01-06 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING |
| GB201705504D0 (en) | 2017-04-05 | 2017-05-17 | Adaptimmune Ltd | Methods of isolating naïve regulatory T cells |
| WO2018200582A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| US20200377855A1 (en) | 2017-05-05 | 2020-12-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rapid method for the culture of tumor infiltrating lymphocytes |
| WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| US12226479B2 (en) | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| TW201919662A (zh) | 2017-06-05 | 2019-06-01 | 美商艾歐凡斯生物治療公司 | 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法 |
| WO2019014684A1 (en) | 2017-07-14 | 2019-01-17 | Ohio State Innovation Foundation | EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| US12036241B2 (en) | 2017-07-19 | 2024-07-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP4516896A3 (en) | 2017-08-09 | 2025-05-14 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
| WO2019040590A1 (en) | 2017-08-22 | 2019-02-28 | Translate Bio Ma, Inc. | MODULATION OF THE EXPRESSION OF SOLUBLE FAS |
| WO2019036815A1 (en) | 2017-08-24 | 2019-02-28 | The Royal Institution For The Advancement Of Learning/Mcgill University | ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP)) |
| BR112020005552A2 (pt) | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| WO2019068099A1 (en) | 2017-09-29 | 2019-04-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF LYMPHOCYTE ACTIVITY SUPPRESSION |
| WO2019077062A1 (en) | 2017-10-18 | 2019-04-25 | Vivia Biotech, S.L. | C-CELLS ACTIVATED BY BIT |
| EP3701041A4 (en) | 2017-10-27 | 2021-11-17 | The Trustees of The University of Pennsylvania | METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASES ASSOCIATED WITH EXHAUSTED T-CELLS |
| US20190127694A1 (en) | 2017-10-27 | 2019-05-02 | Augusta University Research Institute, Inc. | Induced Stem Memory T-Cells and Methods of Use Thereof |
| CA3081479A1 (en) | 2017-11-06 | 2019-05-09 | Ludwig Institute For Cancer Research Ltd | Method for expansion of lymphocytes |
| JP7054418B2 (ja) | 2017-11-08 | 2022-04-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物及び方法 |
| JP7557367B2 (ja) | 2017-11-17 | 2024-09-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 細針吸引及び小生検からのtil拡大培養 |
| EP3724885A2 (en) | 2017-12-15 | 2020-10-21 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| CA3087948A1 (en) | 2018-01-10 | 2019-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of expansion of t cell populations |
| GB201801067D0 (en) | 2018-01-23 | 2018-03-07 | Price Nicola Kaye | Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof |
| CA3090795A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US12173317B2 (en) | 2018-03-28 | 2024-12-24 | Board Of Regents, The University Of Texas System | Use of histone modifiers to reprogram effector T cells |
| EA202092319A1 (ru) | 2018-03-29 | 2021-03-04 | Айовэнс Байотерапьютикс, Инк. | Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии |
| WO2019201970A1 (en) | 2018-04-19 | 2019-10-24 | University Of Copenhagen | A mertk ligand for adoptive t cell cancer therapy |
| CN112262212B (zh) * | 2018-04-24 | 2024-07-12 | 美国卫生和人力服务部 | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| EP3794104A4 (en) | 2018-05-18 | 2022-06-08 | Children's Research Institute, Children's National Medical Center | CELL EXPANSION SYSTEM AND METHODS OF USING THE SAME |
| WO2019227176A1 (en) | 2018-06-01 | 2019-12-05 | Monash University | Methods of activating cells via ptp 1b inhibition |
| US20210236547A1 (en) | 2018-06-05 | 2021-08-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rapid production, expansion, and increased purity of car-t cells using beads with protein l |
| US12668776B2 (en) | 2018-06-05 | 2026-06-30 | H.Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells comprising protein L for expanding immune cells for immunotherapy |
| US20210379106A1 (en) | 2018-06-14 | 2021-12-09 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for enhancing car t cell function |
| WO2020021114A1 (en) | 2018-07-27 | 2020-01-30 | Nordwest Polybiocept Bioscience Gmbh | Method for the treatment of a tumor patient with adoptive t cell immunotherapy |
| EP3830249A1 (en) | 2018-07-31 | 2021-06-09 | polybliocept GmbH | Production and selection of tumor uber reactive immune cells (turics) |
| EP3830114A4 (en) | 2018-07-31 | 2022-08-03 | Washington University | USE OF INTERLEUKIN-7 AND CHIMERA ANTIGEN RECEPTOR (CAR) IMMUNE EFFECTOR CELLS FOR TUMOR TREATMENT |
| JP2021534747A (ja) | 2018-08-22 | 2021-12-16 | セレクト バイオセラピューティクス リミテッド | アポトーシス感受性細胞のモジュレーション |
| CA3110089A1 (en) | 2018-08-28 | 2020-03-05 | Fred Hutchinson Cancer Research Center | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
| SI3844267T1 (sl) | 2018-08-31 | 2025-10-30 | Novartis Ag | Postopki izdelave celic, ki izražajo receptorje himernega antigena |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療 |
| SG11202101787XA (en) | 2018-09-20 | 2021-04-29 | Iovance Biotherapeutics Inc | Expansion of tils from cryopreserved tumor samples |
| US20220002673A1 (en) | 2018-09-24 | 2022-01-06 | John Ellis Mullinax | Culture of tumor infiltrating lymphocytes from tumor digest |
| EP3866814A4 (en) | 2018-10-18 | 2022-07-27 | Board of Regents, The University of Texas System | METHOD OF GENERATING TISSUE-RESIDENT MEMORY-LIKE T-CELLS AND THEIR USE |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| US20220002674A1 (en) | 2018-10-31 | 2022-01-06 | Bellicum Pharmaceuticals, Inc. | T cells with suicide switch |
| EP3873539A4 (en) | 2018-10-31 | 2023-01-18 | The Children's Hospital of Philadelphia | LYMPH-BASED T-CELLS FOR DIAGNOSTIC AND THERAPEUTIC USE |
| CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| US12453697B2 (en) | 2018-11-05 | 2025-10-28 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| BR112021008549A2 (pt) | 2018-11-05 | 2022-01-04 | Iovance Biotherapeutics Inc | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor |
| IL282775B1 (en) | 2018-11-05 | 2026-05-01 | Iovance Biotherapeutics Inc | Selection of enhanced carrier-reactive T cells |
| JP7863702B2 (ja) | 2018-11-08 | 2026-05-22 | セルキュア インコーポレイテッド | 表現型特性が向上したt細胞組成物 |
| US12168781B2 (en) | 2018-12-06 | 2024-12-17 | Kirin Holdings Kabushiki Kaisha | Production method for T cells or NK cells, medium for culturing T cells or NK cells, method for culturing T cells or NK cells, method for maintaining undifferentiated state of undifferentiated T cells, and growth-accelerating agent for T cells or NK cells |
| WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| US20220112557A1 (en) | 2019-01-10 | 2022-04-14 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
| KR20200092155A (ko) | 2019-01-24 | 2020-08-03 | 울산대학교 산학협력단 | 종양침윤림프구를 유효성분으로 포함하는 삼중음성 유방암 예방 또는 치료용 조성물 |
| EP3921419B1 (en) | 2019-02-08 | 2026-04-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Sirt2-ablated chimeric t cells |
| SG11202109331QA (en) | 2019-03-01 | 2021-09-29 | Iovance Biotherapeutics Inc | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2020177071A1 (zh) | 2019-03-05 | 2020-09-10 | 上海鑫湾生物科技有限公司 | 体外诱导和/或扩增tscm的组合物、培养基和方法 |
| CU24712B1 (es) | 2019-03-15 | 2024-07-10 | Centre Hospitalier Univ Vaudois | Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva |
| AU2020254699A1 (en) | 2019-04-05 | 2021-12-02 | 2Seventy Bio, Inc. | Manufacturing anti-BCMA CAR T cells |
| EP3959305A1 (en) * | 2019-04-26 | 2022-03-02 | Allogene Therapeutics, Inc. | Methods of manufacturing allogeneic car t cells |
| CN110157680A (zh) | 2019-05-08 | 2019-08-23 | 浙江大学 | 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法 |
| TWI867324B (zh) | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| KR102081585B1 (ko) | 2019-05-16 | 2020-02-26 | (주)녹십자셀 | 활성화 림프구 및 이의 제조 방법 |
| CA3144640A1 (en) | 2019-06-24 | 2020-12-30 | Children's Hospital Los Angeles | Bcl11b overexpression to enhance human thymopoiesis and t cell function |
| CA3145196A1 (en) | 2019-06-24 | 2020-12-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes |
| CA3144413A1 (en) | 2019-07-17 | 2021-01-21 | Rafick-Pierre Sekaly | Long lived t cells for treating hiv infection |
| GB201910605D0 (en) | 2019-07-24 | 2019-09-04 | Immetacyte Ltd | Tumour infltracting lymphocyte therapy amd uses thereo |
| US20220268762A1 (en) | 2019-07-28 | 2022-08-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods, systems, and computer-readable media for predicting a cancer patient's response to immune-based or targeted therapy |
| WO2021026290A1 (en) | 2019-08-07 | 2021-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cells having enhanced anti-tumor activity |
| US12642809B2 (en) | 2019-08-16 | 2026-06-02 | H. Lee Moffitt Cancer Center And Research Institute | Fucosylation and immune modulation in cancer |
| WO2021046134A1 (en) | 2019-09-03 | 2021-03-11 | Allogene Therapeutics, Inc. | Methods of preparing t cells for t cell therapy |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| EP4048295A1 (en) | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2021108455A1 (en) | 2019-11-25 | 2021-06-03 | KSQ Therapeutics, Inc. | Methods for activation and expansion of tumor infiltrating lymphocytes |
| IL293350A (en) | 2019-11-27 | 2022-07-01 | Myst Therapeutics Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| US12516291B2 (en) | 2019-12-11 | 2026-01-06 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same |
| CA3161510A1 (en) | 2019-12-18 | 2021-06-24 | CBio A/S | Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use |
| JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ (ユーケイ) リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| US20230036952A1 (en) | 2020-01-07 | 2023-02-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of producing t cell populations using induced pluripotent stem cells |
| WO2021167908A1 (en) | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| JP2023516300A (ja) | 2020-02-28 | 2023-04-19 | ケーエスキュー セラピューティクス, インコーポレイテッド | 腫瘍浸潤リンパ球の活性化及び増殖のための方法 |
| CN111440773B (zh) | 2020-04-07 | 2023-03-14 | 上海交通大学 | 一种t细胞体外嵌合抗原受体改造及扩增的优化培养方法 |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| MX2023005492A (es) | 2020-11-23 | 2023-07-27 | Lyell Immunopharma Inc | Métodos de cultivo de células inmunitarias. |
| CN117083376A (zh) * | 2021-02-25 | 2023-11-17 | 莱尔免疫制药公司 | 用于培养细胞的方法 |
| AU2022226660A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN118451098A (zh) * | 2021-10-28 | 2024-08-06 | 莱尔免疫制药公司 | 培养表达c-jun的细胞的方法 |
| WO2023076511A1 (en) * | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods of generating cells |
| CN118308300A (zh) * | 2024-04-16 | 2024-07-09 | 苏州纽博立科技有限公司 | 一种用于t细胞体外培养的细胞培养基及其制备方法和应用 |
-
2021
- 2021-04-28 WO PCT/US2021/029762 patent/WO2021222479A1/en not_active Ceased
- 2021-04-28 MX MX2022013599A patent/MX2022013599A/es unknown
- 2021-04-28 JP JP2022566107A patent/JP2023524047A/ja active Pending
- 2021-04-28 AU AU2021265797A patent/AU2021265797A1/en active Pending
- 2021-04-28 IL IL297751A patent/IL297751A/en unknown
- 2021-04-28 US US17/243,566 patent/US12365871B2/en active Active
- 2021-04-28 EP EP21726301.1A patent/EP4143300A1/en active Pending
- 2021-04-28 BR BR112022021551A patent/BR112022021551A2/pt not_active Application Discontinuation
- 2021-04-28 CA CA3158133A patent/CA3158133A1/en active Pending
- 2021-04-28 CN CN202180044405.3A patent/CN115768879A/zh active Pending
- 2021-04-28 KR KR1020227041750A patent/KR20230017786A/ko active Pending
-
2025
- 2025-06-11 US US19/235,216 patent/US20260008999A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107074975A (zh) * | 2014-08-28 | 2017-08-18 | 生物蛋白有限公司 | 用于修饰的t细胞的条件活性嵌合抗原受体 |
| JP2020511978A (ja) * | 2017-03-31 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 灌流培地 |
| WO2019072889A1 (en) * | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | MEDIUM OF INFUSION |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260008999A1 (en) | 2026-01-08 |
| US12365871B2 (en) | 2025-07-22 |
| WO2021222479A9 (en) | 2022-08-11 |
| US20210332326A1 (en) | 2021-10-28 |
| WO2021222479A1 (en) | 2021-11-04 |
| EP4143300A1 (en) | 2023-03-08 |
| KR20230017786A (ko) | 2023-02-06 |
| CA3158133A1 (en) | 2021-11-04 |
| AU2021265797A1 (en) | 2022-12-08 |
| CN115768879A (zh) | 2023-03-07 |
| IL297751A (en) | 2022-12-01 |
| BR112022021551A2 (pt) | 2023-01-03 |
| MX2022013599A (es) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12365871B2 (en) | Methods for culturing cells | |
| JP7258364B2 (ja) | がんおよび関連悪性腫瘍の治療のためのγδT細胞を活性化、修飾、および増殖させる方法 | |
| US11266689B2 (en) | NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| JP2024509095A (ja) | 細胞の培養方法 | |
| CN111629734A (zh) | 用于共刺激的新型平台、新型car设计以及过继性细胞疗法的其他增强 | |
| WO2021021963A1 (en) | Nk cell composition and preparations for immunotherapy and methods for their production | |
| US20230181644A1 (en) | Methods of generating cells | |
| US20230313138A1 (en) | Methods for culturing cells expressing c-jun | |
| CN117083376A (zh) | 用于培养细胞的方法 | |
| US20250228939A1 (en) | Enhanced immune cell therapy | |
| WO2026006604A1 (en) | Feeder cell replacement | |
| WO2025217398A1 (en) | Methods for culturing cells with improved culture medium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240426 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250909 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260403 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260703 |